Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: November 6, 2013
Reporting Period: Quarter ended September 30, 2013
This filing serves as a notification that the company announced its financial results for the third quarter of 2013. The detailed financial data is contained within the press release furnished as Exhibit 99.1, which is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the press release (Exhibit 99.1) but are not present in the body of this Form 8-K summary.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. It only confirms the announcement of results for the quarter ended September 30, 2013.
Guidance, Outlook, and Risks
The text does not include management commentary, forward-looking guidance, specific risks, contingencies, or unusual items. It strictly references the existence of a press release containing the full announcement.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 6, 2013) for actual revenue, net loss, and cash position figures.
- Verify the specific clinical trial milestones or regulatory updates mentioned in the full press release, as these are not detailed in the 8-K text.
- Confirm the company's cash runway and burn rate from the detailed financial statements referenced in the exhibit.
- Check for any updated guidance on future product launches or partnership agreements in the full announcement.